|
Tavaborole Topical solution is equivalent to reference listed drug, Kerydin Topical solution. Tavaborole Topical solution is indicated to treat fungal toenail infections (infections that may cause nail discoloration, splitting, or pain).
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India).
Tavaborole Topical Solution, 5% had annual sales of $3.1 million in the United States (IQVIA MAT February 2023).
As on 31 December 2022, the group now has 361 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company's consolidated net profit jumped 24.5% to Rs 622.90 crore on 17.9% rise in net sales to Rs 4,159.80 crore in Q3 FY23 over Q3 FY22.
The shares of Zydus Lifesciences were up 0.97% to Rs 501.30 on the BSE. The scrip hit a 52 week high of Rs 501.55 in intraday today.
|